This review demonstrates that quality of evidence behind the use of deep venous stenting to treat obstructive chronic venous disease is weak. However, the consistent effects and marked changes to disease course mean that it should be considered as an acceptable treatment. This review intended to influence clinical practice so vascular teams are aware of this, and it will serve to guide the future research that is needed.
INTRODUCTION
Chronic venous disease (CVD) is common and is defined as a "morphological or functional abnormality of the venous system of long duration" 1 with signs and symptoms ranging from mild leg pain to skin changes, venous claudication, or ulceration. CVD can result from primary or secondary causes, for example where CVD occurs after deep vein thrombosis (DVT), it is known as the post-thrombotic syndrome (PTS), 1 and from extrinsic iliac vein compression, it is known as non-thrombotic iliac vein lesions (NIVLs).
PTS is the most frequent chronic complication of DVT, affecting up to half of patients despite adequate anticoagulation, 2, 3 and carries significant negative impacts on quality of life (QOL) 4 and on the economy. 5 The pathophysiology of PTS is thought to be due to venous hypertension from residual obstruction and deep venous reflux secondary to valve damage. 6 Only 20e30% of iliac vein DVTs fully recananalise 7, 8 and residual obstruction following iliofemoral DVT is associated with severe CVD. 9 Surgical bypass of occluded veins has now been largely superseded by endovenous stenting to treat severe obstructive venous disease. 10, 11 When symptomatic, the pulsatile compression of the left common iliac vein by the right common iliac artery on the fifth lumbar vertebra is referred to as the MayeThurner syndrome. 12 Several other anatomical variants have been described in the literature, such that these lesions are now collectively referred to as (NIVLs) . NIVL may present as a DVT or with CVD. For those presenting with CVD, endovascular stenting is rapidly becoming the treatment of choice over traditional surgical repair. 13 Despite the widespread recommendation 10, 11 of endovascular stenting for CVD related to outflow obstruction from post-thrombotic changes or NIVL, the one systematic review dedicated to the topic 14 was not reported to recognised standards 15 and was conducted over 2 years ago. This report aims to present an updated systematic review and meta-analysis of the available data regarding the efficacy and safety of venous stenting in CVD due to postthrombotic or NIVL obstruction.
MATERIALS AND METHODS
The Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines 15 were followed. The aims of the study, eligibility criteria, and outcomes were predefined in a protocol.
Ethics approval was not required.
Eligibility criteria
All observational and randomised studies, as defined using the Cochrane Handbook 'List of study design features', 16 were eligible except cross-sectional studies. Participants of all ages suffering from CVD related to post-thrombotic or NIVL obstruction, confirmed on imaging, were included if they received endovenous iliac vein stenting with or without extension of the stent stack (group of adjacent overlapping stents) into the inferior vena cava (IVC) or common femoral vein (CFV) and more caudally or with or without the use of concurrent superficial venous procedures. A minimum of 20 eligible stented limbs and 6 months' follow-up was required. Studies were excluded if they did not report on any of the defined outcomes, if stenting was performed within 6 months of DVT in the stented segment, or if the study populations had CVD related only to obstruction from other causes, for example malignancy. No restriction was made on publication type, language, or date. The primary outcome was any change in severity of CVD as determined by validated measures or scores such as the clinical component of the clinical, aetiology, anatomy, and pathophysiology classification (C of CEAP), 17 the Venous Clinical Severity Score (VCSS), 18 or validated measures of PTS severity such as the Villalta score. 19 Secondary outcomes were validated CVD-specific QOL scores such as the Chronic Venous Insufficiency Questionnaire (CIVIQ) 20 and revisions thereof, the Venous Disability Score (VDS), 18 the Venous Insufficiency Epidemiological and Economic Study instrument (VEINES-QOL/ Sym), 21 or generic QOL scores such as the 36-Item Short Form Health Survey (SF-36); 22 rates of ulcer healing; reports on other signs or symptoms of CVD such a pain or oedema; primary, assisted-primary (AP) and secondary stent patency and complications. A complication was considered major if an event led to surgery or medical management with likely significantly prolonged hospitalisation or it led to further endovascular intervention. Owing to suspected heterogeneity in what complications were reported, the complications have been presented as described in the reports, expressed as a percentage rate per limb stented.
Information sources and search strategy
On July 2, 2015, the Ovid portal (1946 to present) was used to search the MEDLINE and EMBASE databases. The Cochrane Central Register of Controlled Trials was searched simultaneously. The references of included studies and other important publications were hand searched for additional reports.
Study selection
All articles located in the initial search strategy had their abstracts and titles independently screened by two authors (M.S. and A.B.) with any discrepancies resolved by discussion. M.S. and A.B. subsequently reviewed the selected full citations to see if they met the eligibility criteria and handsearched references for further studies. If only an abstract had been published, the authors were contacted for full methodology and results. If this could not be provided, the study was excluded. To avoid the inclusion of duplicate publications of the same data, the data were examined for similarities (e.g. identical start and end dates), and if necessary the authors contacted for clarification.
Data collection process and data items
Two authors (M.S. and A.B) extracted the data from the included studies in a predesigned proforma. Data were extracted for study design; 16 start and end dates; demographics; inclusion criteria; the aetiology of venous obstruction (post-thrombotic or NIVL); the number of patients and limbs where stents were attempted and successfully deployed; whether the lesion was stenotic or a chronic total occlusion (CTO) (i.e. requiring recanalisation); the presence of concurrent superficial or deep venous reflux; stent type, and stent site (above vs. below the inguinal ligament and extending stents into the IVC); the time of stenting after DVT (where applicable); the concurrent use of balloon angioplasty; the concurrent use of superficial venous procedures or other venous surgeries; the outcomes; the antithrombotic regimens used; and the number of withdrawals/loss to follow-up per study. For studies where not all of these data were available, the authors were contacted and any unpublished data obtained is highlighted.
Risk of bias
It became clear from initial literature searches that randomised controlled trials (RCTs) in the field were lacking. The included studies were assessed for several key biases by M.S. and A.B.:
16 selection bias, performance bias, detection bias, attrition bias, and selective reporting bias. Attrition bias was deemed a high risk if the follow-up rate was less than 80%, in the absence of systematic examination of those participants who were lost to follow-up. Bias was also evaluated at outcome level using the GRADE assessment of the evidence. 23 
Summary measures and synthesis of results
Owing to the lack of control groups and the heterogeneous inclusion criteria and outcomes in the studies, it was not deemed appropriate to perform a meta-analysis of the data and planned formal sub-group analyses were not possible (post-thrombotic versus NIVL; CTO versus stenosis; stent site (extension below the inguinal and into the IVC); stent type; the use of concurrent superficial venous procedures and the presence/absence of deep or superficial reflux). Any data looking at the effect of these variables within the included studies were extracted and reported.
RESULTS

Study selection
The search strategy yielded 2,058 results, with 1,821 articles for title and abstract screening once duplicates were removed. Of these, 140 articles were selected for consideration of full text and 16 of these articles met the defined eligibility criteria.
24e39 One group published further data with more patients in a second publication, 27 but the original publication 28 is also referenced as it contains data not reported in the second publication. The more recent, larger dataset is referenced except when the older dataset is specifically referred to. Fifteen unique studies were therefore identified in the literature search and hand searching of key references identified an additional one 40 ( Fig. 1) .
Study characteristics
Fourteen studies were before-and-after studies, 24e27,29,31e 36,38e40 one was a controlled before-and-after study 30 and one was a case series. 37 Endovascular stenting was attempted in 2,649 limbs of 2,431 patients with procedural success in 2,586 (97.6%) and 2,373 (97.6%) respectively. Outcome data from control non-stented limbs were available for nine limbs in one study. 30 Age ranged between a median of 39 32 and 58 years 24, 37 and the female/male ratio ranged between 0.6 30 and 4.2. 31 Two out of 16 studies considered only patients with NIVL (a total of 507 and 483 procedures attempted in limbs and patients respectively), 25, 34 seven considered only patients with PTS (509 limbs and 474 patients) 24,26,30,36,38e40 and seven evaluated a mixture, 27,29,31e33,35,37 with two studies also reporting on a small number of patients who received stents for CVD due to other aetiologies. 31, 32 In four studies, all patients had CTO before stenting (a total of 385 limbs), 32, 36, 39, 40 in nine studies there was a mixture of CTO or stenotic lesions (proportions variably specified as displayed in Table 1 ) 24,26,29e31,34,35,37,38 and in three studies the case mix could not be established despite attempting to contact authors. 25, 27, 33 All studies performed angioplasty before stenting, apart from one where it was not stated. 36 The remainder of the extracted data is summarised in Table 1 .
Quality assessment of studies
The overall quality of the included studies was weak. No RCTs, cohort studies or caseecontrol studies that met the inclusion criteria were identified. One study had a control group 30 and these nine contralateral non-stented limbs were not comparable to the intervention group, as the median C component of CEAP was different at baseline. Three of the more recent reports were conducted prospectively, 24, 27, 33 otherwise they were retrospective 25,26,29,30,32,34e40 and in one case it was not clear. A general strength of the included studies was that several consisted of a substantial number of stented limbs (over 150). 25,27,34e37 Outcomes and grading of the evidence Using the GRADE approach, 23 for five of the six defined outcomes, the quality of evidence was rated as "very low" and for ulcer healing it was rated as "low" ( Table 2 ).
Severity of CVD
Five studies reported one or more of the defined measures of CVD severity with sufficient follow-up duration (a total of 295 stented patients). 24, 26, 30, 31, 39 Delis et al. 30 demonstrated a significant improvement (p < .01) in median CEAP class from C3 (C3e6) to C2 (C2e6) after stenting in 23 PTS limbs at a median of 8.3 months follow-up (100% follow-up rate). There was no change from the baseline C2 (C0e4) CEAP class in the nine contralateral non-stented control limbs. Hartung and colleagues 31 found median VDS decreased from 2 to 1 (0e3) at a median of 38 months' follow-up (100% follow-up rate), but the statistical significance is unclear. Blanch Alerany and colleagues 26 found significant improvements in mean Villalta and VCSS scores (p < .0001) following stenting from 15 (10e28) to 2 (0e11) and 8 (5e17) to 2 (0e9) respectively at a mean of 21 months in their study of 36 PTS patients (29/39 limbs and 12/39 at 12 and 24 month follow-up respectively). Patients whose stents occluded during follow-up, and refused secondary interventions, experienced a sustained, but smaller, decrease in VCSS of at least four points. 26 Sarici et al. 24 showed significant reductions (p < .0001) in median Villalta and VCSS scores of 18 (interquartile range (IQR) 7e30) to 8 (4e19) and 14 (6e28) to 5 (3e17) respectively in 52 PTS patients at 6 months' follow-up (100% follow-up rate), with less marked improvements in the five patients whose stents occluded. Ye et al. 39 showed the mean Villalta score fell from 22.0 AE 4.3 to 9.3 AE 2.6 in 87 of their PTS patients at a median 25-month follow-up.
Other signs and symptoms of CVD All but two studies 27, 37 reported other signs and symptoms of CVD, predominantly oedema and pain, totalling 1,984 patients who received stents (Table 3) .
Ulcer healing
Twelve of the included studies described data on ulcer healing (a total of 400 ulcers).
24e26,30,31,33e36,38e40 The rate of persistent ulcer healing ranged from 56% in a large study of 167 CTO PTS limbs 36 to 100% in several smaller studies. 26, 31, 38 The study with the largest number of patients with ulcers at baseline described a cumulative 5-year healing rate of 58% of the 148 baseline ulcers. 35 Six studies specifically stated that the participants had failed conservative management, 26, 30, 31, 34, 38 and in one study the ulcers had failed to heal after endovenous laser varicosity ablation. 25 In a further two studies the authors were contacted to confirm the patients had indeed failed conservative management. 35, 36 The ulcer healing data are summarised in Table 3 .
Quality of life measures
Three studies reported changes in CVD-specific QOL scores following stenting 24, 28, 36 and one also included a general QOL score (SF-36). 28 Raju and Neglen 36 found significant Endovenous stenting in chronic venous disease 28 they demonstrated that for 33 of 54 of their mixed PTS and NIVL patients at 1 year there were significant improvements (p ¼ .015) in one of the eight domains in the SF-36 (physical functioning) and no domains worsened. Sarici et al. 24 found that the median CIVIQ-20 score significantly improved (p < .001) from 64 of 100 to 83 in their 59 PTS patients at 6 months after intervention (100% follow-up rate).
Stent patency
Fourteen studies reported data on stent patency (a total of 2,410 limbs stented), 24e27,29,31e40 with follow-up duration ranging between 6 months 24 and a median of 4 years. 25 The last available, overall primary patency rates ranged from 32% 36 e98.7%. 25 The same studies also reported the lowest (58% 36 ) and the highest (100% 25 ) AP patency rates. The lowest secondary patency rate was also in Raju and Neglen's 2009 study 36 at 66% and the highest was 96% in two studies. 29, 37 The patency data are summarised in Table 4 .
Complications
Fifteen studies provided data regarding complications, reporting a total of 599 (25 major 40 and De Wolf et al. 29 (also unclear follow-up rate in several others) placing outcome at risk of selection bias and complications reported were not predefined (exception of Liu et al. 33 ) so risk of selective reporting bias. i Minor complication rates varied likely due to the nature of complications that where reported, e.g. back pain. 24,26,29e38,40 studies reporting these data separately from their patency outcomes. The reported complications are summarised in Table 4 .
Subgroup analyses
Where available, the data are summarised in Table 5 . Additionally, two studies used venous-specific stents in a small number 26 or unstated number of limbs 29 (both Zilver Vena; Cook Medical, Bloomington, IN, USA). Six studies used multiple types of stents, 26, 29, 30, 35, 37, 38 and Blanch Alerany et al. 26 found no association between stent brand and stent thrombosis.
DISCUSSION
Endovenous stenting is increasingly used to treat CVD related to PTS and NIVL obstruction. This review demonstrates that the quality of evidence supporting this is weak, with the main flaw being a lack of control groups to illustrate that the observed benefits are not part of the natural progression of CVD. Recent European and American guidelines recommended endovenous stenting for severe obstructive venous disease, but recognised that the evidence is weak. 10, 11 It is recognised that PTS ulcers can be refractory to conservative treatment and tend to recur 6 and this review highlighted six studies 26, 30, 31, 35, 36, 38 where ulcers in PTS limbs failed to heal with conservative measures. The consistent response of ulcer healing to stenting therefore represents a change in the course of the disease and suggests deep venous stenting is an effective therapy for refractory PTS ulcers. The other five outcomes were all largely positive, but firm conclusions about the magnitude of the effect of endovenous stenting in CVD related to obstruction cannot be drawn.
The importance of ensuring a true improvement in a patient's QOL and not just venous severity scores has recently been demonstrated in the setting of endovenous intervention. The CaVenT trial showed reduced rates of PTS in patients two years after receiving catheter-directed thrombolysis for proximal DVT compared to compression and anticoagulation, 41 but no difference in venous diseasespecific QOL scores. 42 This review found general improvements in the various QOL scores, but the methodological weaknesses mean that deep venous stenting has not yet been shown to definitely improve QOL.
If the efficacy of endovenous stenting cannot be quantified, it does appear to be safe, with rates of major complications of less than 2% in all studies which stented over 200 limbs. 25, 34, 35, 37 Minor complications were reported at variable rates, likely to be due to a combination of heterogeneous study groups and inconsistency in classifying or reporting complications. Initiatives such as the stenting section of the American Venous Registry 43 will allow standardisation and more precise estimates of complication rates. The concern from arterial studies of possible stent fracture across joints does not appear to translate to venous stenting, with one stent fracture and two stent kinks in one study only. 29 Despite initial concerns that stents in the low-flow venous system are likely to be at serious risk of thrombosis, all of the included studies demonstrated good patency rates. Primary patency rate was over two-thirds at the last follow-up in all studies apart from two, 27, 37 with over 3 years' of follow-up in several studies. 25, 31, 34, 38 Three studies found that stenting below the inguinal ligament was associated with worse patencies 35, 39, 40 and three did not. 26, 31, 32 Neglen et al. 44 performed a further analysis of their dataset that suggested that patency is not related to extension across the inguinal ligament, but is in fact related to aetiology with better patencies for NIVL than PTS and for non-occlusive lesions versus CTO. This conclusion is supported by the very high patency rates reported in studies where only NIVL were stented, 25, 34 whereas studies with a high proportion of CTO PTS limbs often reported less favourable patencies. 32, 36 It is likely therefore that any worse endovascular outcome with stents below the inguinal ligament reflects the severity of the post-thrombotic obstruction, rather than an inherent danger of caudal stent extension. At the cephalic end, extending stent stacks into the IVC appears safe, with low risk of contralateral DVT, and two studies suggested early stent stenosis if this is not pursued for lesions near the iliac confluence. 24, 35 The concurrent use of superficial venous interventions is certainly a potential confounding factor; however, with the exception of one study, 25 they were performed in the minority of stented limbs 24, 31, 35 suggesting any effect is likely to be largely related to endovenous stenting. The data suggest that surgical inflow procedures can be concurrently performed safely, but given that stenting below the inguinal ligament is likely to be effective, we would argue that this should be pursued first. There was no evidence to suggest that stenting for obstructive lesions in patients with known deep reflux worsens CVD severity, although this was assessed in one study only. 26 Raju's group have corroborated this in a further analysis of their large dataset, which showed that correcting the obstructive element alone of combined obstructive and deep reflux disease, demonstrates clinical improvement without deterioration in reflux measures. 45 The diagnosis of obstruction is beyond the scope of this review, but the inadequacies of duplex ultrasound 46 and contrast venography 47 and the need for other imaging modalities have been documented elsewhere, 11 with intravascular ultrasound showing promise. 47 Furthermore, this review did not aim to examine the combined effect of stenting with medical adjunctive management such as the use of pentoxifylline 11 or aspirin. 48 There are therefore a number of areas for future research. Before the practice is more widely rolled out, a RCT should be performed comparing the practice against conservative measures, with long-term follow-up and outcome measures to include validated CVD measures and QOL scores. 49 
